x
ServiziMenu principaleHome
You are here: Home > What we do > Clinical Training Centres Fellowship Programme > Fellowship Programme - Doctors > Oncology Institute of Southern Switzerland
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Oncology Institute of Southern Switzerland (IOSI)

Bellinzona, Switzerland

Person responsible for CTC programme: PD Dr. Sara De Dosso

Hospital overview

The IOSI is a non-surgical cancer centre covering the needs of the population in the Southern, Italian speaking, part of Switzerland. It comprises 5 clinics: medical oncology, radiation-oncology, haematology, palliative care, and research. Overall, 60 physicians compose the 5 teams. The main centre is in the San Giovanni hospital in Bellinzona, where the inpatient department (31 beds), the direction and the research centre is located, but IOSI covers also the oncology needs of 3 other hospitals, in Lugano, Mendrisio and Locarno. The Institute follows at the moment approximately 8000 patients, with about 2000 new cases per year.

The Oncology Institute of Southern Switzerland is one of the largest clinical research centres in Switzerland. The three main areas of clinical research comprise new drugs development, lymphoproliferative diseases (lymphoma and chronic lymphocytic leukaemia) and prostate cancer. Other areas of development in clinical research include breast, lung and gastrointestinal cancer. The Institute has a central role in the Faculty of Biomedical Sciences of the Università della Svizzera Italiana (USI)

A training period in our Institute is particularly suitable for colleagues interested in experiencing a very collaborative, multidisciplinary and organised functioning, adapted to the reality of medium sized hospitals.

 

CTC programmes offered

1. Hematological malignancies

Discipline: Hematology, Medical Oncology
Programme mentor:

E. Zucca, G. Stüssi, D. Rossi, E. Lerch, A. Stathis, L. Wannesson 

Duration: 3 - 6 months
Type: Visiting Residency and Visiting Observership
Language requirements: Italian language (but most doctors speak English)
Programme description: 1-3 months in the hemato-oncology inpatient department (lymphomas, myelomas, leukemias, autologous transplantation), 2-3 months rotating through the autologous transplantation program, lymphoma clinic, leukemia clinic, myeloma clinic, hematology diagnostic laboratory, lymphoma research team.

2. Solid tumors oncology

Discipline: Medical Oncology, Palliative Care
Programme mentor: I. Colombo, S. De Dosso, V. Espeli, P. Frösch, C. Gamondi, R. Graffeo, L. Rossi, U. Vogl
Duration: 3 - 6 months
Type: Visiting Residency and Visiting Observership
Language requirements: Italian language (but most doctors speak English)
Programme description: 1-2 months in the oncology and palliative care inpatient department (all types of solid tumours), 2-3 months rotating through the GI, lung, breast, gynaecological, H&N and general oncology outpatient clinics. In addition, attendees will be able to see the organisation and functioning of our High Risk Clinic - Oncogentics, that deliver genetic counseling and evaluation for cancer predisposition testing.

3. New drug development

Discipline: Medical Oncology
Programme mentor: A. Stathis
Duration: 3 - 6 months
Type: Visiting Residency and Visiting Observership
Language requirements: Italian language (but most doctors speak English)
Programme description: Activity with both physicians in charge of study patients and with research nurses / data managers, to experience the clinical and administrative patient management, the preparation and the application of clinical protocols, team work, SOP and good clinical practice (GCP).

4. Radiation oncology

Discipline: Radiotherapy
Programme mentor: M.C. Valli, G. Pesce
Duration: 3 - 6 months
Type: Visiting Residency and Visiting Observership
Language requirements: Italian language (but most doctors speak English)
Programme description:

A customized program will be developed on the clinical, technical and dosimetric aspects of RT in the treatment of solid cancers i.e. SNC, head and neck, gastrointestinal, lung, breast, genitourinary, cutaneous and hematological ones i.e.lymphoma. The palliative role of RT will be analyzed too.
We will be able to host radiation oncologists as well as physicists or radiographers as solely candidate or as complete staff, adapting the arguments' approach on demand. In a multidisciplinary approach, all aspects from conventional/conformal to very advanced intensity modulated RT can be covered.